Lv4
600 积分 2021-08-25 加入
882-P: Eloralintide, a Selective, Long-Acting Amylin Receptor Agonist for Obesity—Phase 1 Proof of Concept
1个月前
已完结
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
1个月前
已完结
849-P: Eloralintide (LY3841136), a Selective Amylin Mimetic, Lowered Body Weight with Improved Quality of Weight Loss and GI Tolerability in Rats Compared with Cagrilintide
1个月前
已完结
882-P: Eloralintide, a Selective, Long-Acting Amylin Receptor Agonist for Obesity—Phase 1 Proof of Concept
1个月前
已完结
Regulation of GLP-1 and Glucagon Receptor Function by β-Arrestins in Metabolically Important Cell Types
3个月前
已完结
BCL-2 in leukemia: Enhancing clinical utility
3个月前
已完结
What does BCL-2 do? From new molecular insights to the clinical implications
3个月前
已完结
Monomeric or Homodimer Conjugates of Fibroblast Activation Protein Inhibitor and Cyanine 7 Bearing a Meso-Chloride as Near-Infrared Fluorescence Probes: Design, Synthesis, and Comparative In Vivo Imaging of Distinct Breast Cancer Subtypes
4个月前
已完结
Mirvetuximab Soravtansine: Mechanism of Action, Clinical and Translational Science
4个月前
已完结
Decoding tumors from fibroblast activation protein: A review of the latest diagnostic and therapeutic prospects
4个月前
已完结
皖公网安备34019202002308
